<DOC>
	<DOCNO>NCT00085826</DOCNO>
	<brief_summary>Taxotere approve FDA consider standard treatment patient lung cancer fail prior platinum-containing regimen . The main purpose research study determine Aptosyn , give combination Taxotere , result prolong survival compare Taxotere alone . This study also help determine tumor response rate , safety profile Aptosyn combination Taxotere . This study complete publication pending .</brief_summary>
	<brief_title>A Phase III Study Efficacy Taxotere/Aptosyn Versus Taxotere/Placebo Non-Small Cell Lung Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Sulindac sulfone</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria />
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Non-small Cell Lung Cancer</keyword>
</DOC>